From Infusion to Concern: How Clinicians Evaluate Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Legal Context

If you or a loved one has taken Tysabri and now face a potential PML diagnosis, understanding how clinicians evaluate the risk is crucial. For decades, pharmacovigilance research has established that cumulative dose and treatment duration are central to assessing PML risk. This page explains the diagnostic pathway and what the medical evidence shows.

Tysabri and PML: Medical Background and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can be rapidly progressive, the label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, adverse event reports submitted to the FDA's FAERS database list PML-related symptoms among the most frequently reported events for Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of early recognition and prompt intervention.

Mechanism of Action and Legal Implications

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of lymphocytes, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for controlling multiple sclerosis relapses. However, this same mechanism impairs immune surveillance against JCV, allowing the virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus and potential for reactivation. For patients who develop PML after Tysabri exposure, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The boxed warning on the label explicitly states the increased risk of PML and the need for enrollment in the TOUCH Prescribing Program, a restricted distribution program designed to ensure informed consent and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether the warnings were sufficiently clear or timely, especially for patients who developed PML after prolonged therapy. The timeline between exposure and documented harm is critical: PML can occur after months to years of treatment, and the label notes that duration beyond two years is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

California Statute of Limitations for Tysabri-Related Claims

For patients in California, the statute of limitations for filing a personal injury lawsuit related to Tysabri and PML is generally two years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. This timeline may be affected by the latency period of PML, which can delay diagnosis and recognition of the link to Tysabri. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and monitoring requirements outlined in its prescribing information. Patients who develop PML may face severe disability or death, and the adequacy of warnings and the timing of harm are central to any legal evaluation. For affected individuals in California, understanding the statute of limitations is essential for preserving legal rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for personal injury claims related to Tysabri and PML is generally two years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Due to the latency of PML, this timeline may be extended if the injury was not immediately apparent.

What are the main risk factors for developing PML while on Tysabri?

The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when assessing the risk of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.